Advertisement
News
Subscribe to MDT Magazine News

Aetna's 4Q profit jumps 30 percent(2)

February 4, 2011 1:46 am | by The Associated Press | Comments

Health insurer Aetna says its fourth-quarter net income rose 30 percent as it benefited from higher pricing and a slowdown in health care use that also has helped its competitors.The Hartford, Conn., insurer said Friday it earned $215.6 million, or 53 cents per share, in the three months that...

Aetna's 4Q profit jumps 30 percent

February 4, 2011 1:46 am | Comments

Health insurer Aetna says its fourth-quarter net income rose 30 percent as it benefited from higher pricing and a slowdown in health care use that also has helped its competitors.The Hartford, Conn., insurer said Friday it earned $215.6 million, or 53 cents per share, in the three months that...

FDA Grants Orphan Drug Designation to Bayer's Investigational Compound Regorafenib for the Treatment of Gastrointestinal Stromal Tumors

February 4, 2011 12:34 am | by Bio-Medicine.Org | Comments

WAYNE, N.J., Feb. 4, 2011 /- Bayer HealthCare Pharmaceuticals Inc. announced today that its investigational compound regorafenib (BAY 73-4506) has been granted orphan drug status for the treatment of patients with gastrointestinal stromal tumors (GIST) by the U.S. Food and Drug...

TOPICS:
Advertisement

Family mealtimes play a role in health of children with asthma

February 3, 2011 8:33 pm | by EurekAlert | Comments

(Society for Research in Child Development) Researchers studying 200 families with children ages 5-12 who had persistent asthma observed how they interacted during a video-recorded meal in their homes. They found that the quality of social interactions as families ate was directly related...

TOPICS:

Report says economic development could change worldwide face of cancer

February 3, 2011 8:33 pm | by EurekAlert | Comments

(American Cancer Society) A new American Cancer Society report says cancers associated with lifestyles and behaviors related to economic development, including lung, breast, and colorectal cancers, will continue to rise in developing countries if preventive measures are not widely applied.

TOPICS:

Researchers "Grow" New Blood Vessels

February 3, 2011 7:32 pm | by Massachusetts Institute of Technology | Comments

The synthetic vessels can be stored for long periods and avoid the complications typical of vessel grafts.

TOPICS:

CareFusion 2Q profit rises, company pares outlook

February 3, 2011 5:45 pm | by The Associated Press | Comments

Medical device maker CareFusion Corp. said Thursday its profit increased 9 percent in the fiscal second quarter as cost cuts offset a decline in sales.The company said its profit rose to $76 million, or 34 cents per share, from $70 million, or 32 cents per share. Excluding items like...

FDA sued over shipments of drug used in executions

February 3, 2011 12:45 pm | by GREG BLUESTEIN - Associated Press - Associated Press | Comments

A federal lawsuit filed against the Food and Drug Administration urges a judge to block overseas shipments of a key drug used in the nation's executions that has been in short supply since the sole U.S. maker decided to stop producing it.The lawsuit filed Wednesday in federal court in Washington,...

Advertisement

US agency sued over drug used in executions

February 3, 2011 12:45 pm | by GREG BLUESTEIN - Associated Press - Associated Press | Comments

A federal lawsuit filed against the Food and Drug Administration urges a judge to block overseas shipments of a key drug used in the nation's executions that has been in short supply since the sole U.S. maker decided to stop producing it.The lawsuit filed Wednesday in federal court in...

Using a generic blood pressure and heart drug could save the UK $324 million in 2011

February 3, 2011 12:38 pm | by EurekAlert | Comments

(Wiley-Blackwell) Using a generic drug to treat hypertension and heart failure, instead of branded medicines from the same class, could save the UK's National Health Service at least £200 ($324) million in 2011 without any real reduction in clinical benefits. That is the key...

TOPICS:

Death in the bat caves: Disease wiping out hibernating bats

February 3, 2011 11:39 am | by EurekAlert | Comments

(Wiley-Blackwell) Conservationists across the United States are racing to discover a solution to white-nose syndrome, a disease that is threatening to wipe out bat species across North America. A review published in Conservation Biology reveals that although WNS has already killed...

TOPICS:

CareFusion to sell unit for $130M to Medline

February 3, 2011 10:45 am | by The Associated Press | Comments

CareFusion Corp. said Thursday it will sell its surgical products unit to privately-held Medline Industries for $130 million.CareFusion's surgical products business is based in based in Rolle, Switzerland, with operations in 16 European and Asian-Pacific countries and distribution and assembly...

Microchips moves osteoporosis device into clinical study

February 3, 2011 9:38 am | by Mass High Tech: The Journal of New England Technology | Comments

Some 18 years after MIT professor Robert Langer first envisioned using an implantable reservoir as a drug delivery device, one of his companies, MicroCHIPS Inc. of Bedford, announced today that it is initiating a clinical study of a device that delivers a peptide over the course of months...

ConforMIS knee replacement tech get FDA marketing nod

February 3, 2011 9:38 am | by Mass High Tech: The Journal of New England Technology | Comments

Burlington-based medical devices company ConforMIS Inc. has received 510k clearance from the U.S. Food and Drug Administration to commercially market its iTotal CR Knee Replacement System.

Psivida eyes opportunities in off-patent drugs

February 3, 2011 9:37 am | by Mass High Tech: The Journal of New England Technology | Comments

PSivida Corp. of Watertown is breathing new life into off-patent drugs by using them with its miniaturized drug-delivery products, which deliver lower, time-released doses of therapies for longer periods. And it's scheduled today to release three-year data from two Phase 3 clinical trials...

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading